Scientists unravel breast cancer drug resistance

By Michael Kahn

LONDON (Reuters) - British scientists have figured out why some women develop resistance to the most commonly used breast cancer drug, something that raises the risk their tumors will return, according to a study published on Wednesday.

The findings could lead to new tests to determine which women are not likely to benefit from tamoxifen and who should be given other drugs, said Jason Carroll of Cancer Research UK in Cambridge, who led the study published in the journal Nature.

"We can use this information to predict which patients will respond to tamoxifen and more importantly which ones won't," Carroll told reporters in a telephone briefing.

"More importantly it gives us an idea of what we should be making drugs against."

Breast cancer is the leading cause of cancer deaths among women worldwide, according to the American Cancer Society. The group estimates about 465,000 women died of breast cancer globally in 2007, and 1.3 million new cases were diagnosed.

Declining death rates from breast cancer in developed countries have been attributed to early detection through mammography screening and to improved treatment.

Tamoxifen is given to most women for five years after they are diagnosed with breast cancer to prevent the disease from returning, but some women develop resistance, which means their tumor is more likely to recur.

The drug works by blocking estrogen from causing wild cell growth in breast cancer by switching certain genes on, but how this exactly happened was unknown, the researchers said.